X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA AUROBINDO PHARMA AJANTA PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 28.3 15.6 181.1% View Chart
P/BV x 11.7 4.0 290.9% View Chart
Dividend Yield % 0.5 0.4 132.2%  

Financials

 AJANTA PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
AUROBINDO PHARMA
Mar-17
AJANTA PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,720895 192.2%   
Low Rs1,103622 177.3%   
Sales per share (Unadj.) Rs194.6254.6 76.4%  
Earnings per share (Unadj.) Rs45.239.3 115.1%  
Cash flow per share (Unadj.) Rs50.346.6 108.0%  
Dividends per share (Unadj.) Rs8.002.50 320.0%  
Dividend yield (eoy) %0.60.3 172.0%  
Book value per share (Unadj.) Rs132.0160.0 82.5%  
Shares outstanding (eoy) m88.77585.88 15.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.33.0 243.4%   
Avg P/E ratio x31.219.3 161.6%  
P/CF ratio (eoy) x28.116.3 172.3%  
Price / Book Value ratio x10.74.7 225.5%  
Dividend payout %17.76.4 278.0%   
Avg Mkt Cap Rs m125,299444,390 28.2%   
No. of employees `000NA14.0 0.0%   
Total wages/salary Rs m2,57017,678 14.5%   
Avg. sales/employee Rs ThNM10,667.8-  
Avg. wages/employee Rs ThNM1,264.3-  
Avg. net profit/employee Rs ThNM1,645.8-  
INCOME DATA
Net Sales Rs m17,275149,157 11.6%  
Other income Rs m1661,159 14.3%   
Total revenues Rs m17,442150,316 11.6%   
Gross profit Rs m5,80734,343 16.9%  
Depreciation Rs m4514,276 10.5%   
Interest Rs m49667 7.3%   
Profit before tax Rs m5,47430,558 17.9%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,4607,597 19.2%   
Profit after tax Rs m4,01423,012 17.4%  
Gross profit margin %33.623.0 146.0%  
Effective tax rate %26.724.9 107.3%   
Net profit margin %23.215.4 150.6%  
BALANCE SHEET DATA
Current assets Rs m7,63992,062 8.3%   
Current liabilities Rs m2,71566,223 4.1%   
Net working cap to sales %28.517.3 164.5%  
Current ratio x2.81.4 202.4%  
Inventory Days Days43106 40.8%  
Debtors Days Days7968 116.3%  
Net fixed assets Rs m6,91462,919 11.0%   
Share capital Rs m177586 30.2%   
"Free" reserves Rs m11,44293,133 12.3%   
Net worth Rs m11,72193,719 12.5%   
Long term debt Rs m1491,814 8.2%   
Total assets Rs m14,814162,494 9.1%  
Interest coverage x112.946.8 241.3%   
Debt to equity ratio x00 65.5%  
Sales to assets ratio x1.20.9 127.0%   
Return on assets %27.414.6 188.2%  
Return on equity %34.224.6 139.5%  
Return on capital %46.532.7 142.1%  
Exports to sales %55.10-   
Imports to sales %6.00-   
Exports (fob) Rs m9,527NA-   
Imports (cif) Rs m1,038NA-   
Fx inflow Rs m10,42275,838 13.7%   
Fx outflow Rs m1,67830,224 5.6%   
Net fx Rs m8,74445,613 19.2%   
CASH FLOW
From Operations Rs m3,26432,786 10.0%  
From Investments Rs m-2,093-17,870 11.7%  
From Financial Activity Rs m-1,186-19,153 6.2%  
Net Cashflow Rs m-15-4,239 0.3%  

Share Holding

Indian Promoters % 73.8 54.1 136.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 8.0 19.5%  
FIIs % 7.6 27.7 27.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 10.2 166.7%  
Shareholders   20,968 69,601 30.1%  
Pledged promoter(s) holding % 4.4 8.6 51.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ORCHID PHARMA LTD  CIPLA  ABBOTT INDIA  UNICHEM LAB  WYETH LTD  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS